Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
Approximately 20 million U.S. adults with inadequately controlled LDL-C may be eligible for inclisiran, with the potential to prevent over 1.6 million ASCVD events over 10 years.
Authors
- Hridhay Karthikeyan
- Batul Electricwala
- Nathan D. Wong
- Wenjun Fan
Institutions
- University of California, Irvine (US)
- Novartis (United States) (US)
Publication Details
- Journal
- JACC Advances
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1016/j.jacadv.2025.102517
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00